Multiparameter diagnostic model using S100A9, CCL5 and blood biomarkers for nasopharyngeal carcinoma

利用S100A9、CCL5和血液生物标志物构建鼻咽癌多参数诊断模型

阅读:1

Abstract

This study aimed to analyze S100A9 and CCL5 levels in patients with nasopharyngeal carcinoma (NPC) and evaluate their predictive value as blood-based indicators for NPC diagnosis. Serum S100A9 and CCL5 levels were measured in 123 patients newly diagnosed with NPC and 107 patients without NPC. Additionally, 38 patients (19 with NPC and 19 without) were recruited from Xiangya Hospital as an external validation cohort. Logistic regression was used to identify risk factors for NPC. Variable selection was conducted using least absolute shrinkage and selection operator (LASSO) regression. NPC prediction models were developed using four machine-learning algorithms, and their performance was evaluated with ROC curves. Calibration curves, decision curve analysis (DCA), and Shapley additive explanation plots were employed for further evaluation and interpretation. Serum S100A9 and CCL5 levels were significantly elevated in patients with NPC compared with patients without NPC. Multivariate logistic regression identified S100A9, CCL5, TP, and ALB as independent predictors of NPC. ROC analysis demonstrated that S100A9 had superior diagnostic performance compared to CCL5 and other blood indicators, effectively differentiating NPC from non-NPC cases. A machine-learning-based logistic regression model incorporating S100A9, CCL5, ALB, GLB, and PLR demonstrated a reliable diagnostic value for NPC, achieving an Area under the curve (AUC) of 0.877 in the training cohort. The calibration curve showed excellent agreement between predicted and actual probabilities; in contrast, the DCA curve highlighted strong clinical utility. The model also performed well in the external validation cohort, with an AUC of 0.817. Serum levels of S100A9, CCL5, and other indicators such as GLB, ALB, and PLR have diagnostic values for NPC. The logistic regression model based on these biomarkers demonstrated robust predictive performance and clinical utility for NPC diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。